Repurposing Cilnidipine as an entry inhibitor against Crimean–Congo Hemorrhagic Fever pseudovirus infection
Archives of Virology · 2026
DOI: 10.1007/s00705-026-06588-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archives of Virology, 2026. Verfasst von Sujata Gupta und 5 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Virus Research, Therapeutics and Vaccines, BRIC-Translational Health Science & Technology Institute, NCR Biotech Science Cluster, Faridaba…. Hauptthemen laut MEDLINE: Dihydropyridines, Virus Internalization, Drug Repositioning, Antiviral Agents. Die Arbeit nennt 60 Literaturangaben. Gefördert von: Defence Research and Development Organisation.
Abstract (Originalsprache)
Crimean-Congo hemorrhagic fever virus (CCHFV), a tick-borne pathogen of the Nairoviridae family, is classified as a high-risk biosafety level-4 (BSL-4) agent, which restricts its handling and limits mechanistic investigations. To overcome these challenges, we developed a CCHF pseudovirus as a safe and reliable surrogate for studying viral entry and evaluating antiviral candidates. Pseudovirus-based systems have proven valuable tools for elucidating viral infection mechanisms, conducting neutralization assays, and screening of small-molecule inhibitors. In the present study, a lentiviral packaging system incorporating CCHFV envelope glycoproteins (Gn and Gc) was established in HEK293T cells to generate infectious pseudovirions. Viral infectivity was quantified using a luciferase reporter assay. Cilnidipine, a clinically approved dual L-type and N-type calcium channel blocker with established antihypertensive activity, was investigated for its potential to inhibit CCHF pseudovirus entry in HEK293T and Huh-7 cells. Treatment with Cilnidipine resulted in a marked, dose-dependent reduction in luciferase signal, suggesting potent inhibition of pseudovirus entry at micromolar concentrations. Co-treatment assays further confirmed its inhibitory action at the early stages of infection. Overall, this study highlights Cilnidipine as a promising repurposed antiviral candidate targeting viral entry pathways. The findings provide a foundation for future mechanistic and pre-clinical evaluations aimed at developing effective therapeutics against CCHFV.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre for Virus Research, Therapeutics and Vaccines, BRIC-Translational Health Science & Technology Institute, NCR Biotech Science Cluster, Faridabad, Haryana, India.
- Manipal Academy of Higher Education, Karnataka, 576104, Manipal, India.
- Centralized Core Research Facility (CCRF), All India Institute of Medical Sciences, New Delhi, 110029, India.
- Centre for Virus Research, Therapeutics and Vaccines, BRIC-Translational Health Science & Technology Institute, NCR Biotech Science Cluster, Faridabad, Haryana, India. sweety.samal@thsti.res.in.
Förderung
- Defence Research and Development Organisation
Zitieren
APA
Gupta, S., Gandhi, L., Baby, B. A., Kaur, G., Ahmed, S., & Samal, S. (2026). Repurposing Cilnidipine as an entry inhibitor against Crimean–Congo Hemorrhagic Fever pseudovirus infection. Archives of Virology. https://doi.org/10.1007/s00705-026-06588-3
Vancouver
Gupta S, Gandhi L, Baby BA, Kaur G, Ahmed S, Samal S. Repurposing Cilnidipine as an entry inhibitor against Crimean–Congo Hemorrhagic Fever pseudovirus infection. Archives of Virology. 2026. doi:10.1007/s00705-026-06588-3
BibTeX
@article{Gupta2026,
author = {Gupta, Sujata and Gandhi, Lekha and Baby, Basil A and Kaur, Gurleen and Ahmed, Shubbir and Samal, Sweety},
title = {Repurposing Cilnidipine as an entry inhibitor against Crimean–Congo Hemorrhagic Fever pseudovirus infection},
journal = {Archives of Virology},
year = {2026},
doi = {10.1007/s00705-026-06588-3}
}
EUVIMED